Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60

Clicks: 446
ID: 114114
1996
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #12 of 86 articles by views in Vaccine

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The safety and immunogenicity of purified fusion protein (PFP-2) respiratory syncytial virus (RSV) vaccine was evaluated in a randomized placebo-controlled, double-blind study of 64 healthy adults over age 60. Vaccination was well tolerated with no significant acute side-effects. Twenty-nine of 33 v …
Reference Key
ar1996vaccinesafety Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Falsey AR;Walsh EE;;
Journal Vaccine
Year 1996
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/8961507
Keywords
vaccination National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't female male aged middle aged 80 and over Clinical Trial Randomized Controlled Trial Antibodies Double-Blind Method respiratory syncytial viruses / immunology* viral / blood viral vaccines / adverse effects* viral vaccines / immunology pmid:8961507 doi:10.1016/s0264-410x(96)00030-8 a r falsey e e walsh

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.